RT-112
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats RT-112 as ChEMBL target CHEMBL614145. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why RT-112 matters
RT-112 is reviewed as RT-112; the current evidence base includes 33 approved drugs, 268 compounds, and 89 assays, with lead potency reaching pChEMBL 9.9.
RT-112
Review this target as RT-112.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 33 approved drugs, 268 compounds, and 89 assays for this target. The dominant activity type is IC50. CHEMBL888 is the current potency anchor at pChEMBL 9.9.
Use CHEMBL888 as the tractability anchor when discussing potency (pChEMBL 9.9).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why RT-112 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL888
|
9.9 | IC50 | Approved |
|
|
No preferred name
CHEMBL3348846
|
9.2 | IC50 | Clinical |
|
|
No preferred name
CHEMBL94657
|
9.2 | IC50 | Clinical |
|
|
No preferred name
CHEMBL3545252
|
8.9 | IC50 | Approved |
|
|
No preferred name
CHEMBL3545376
|
8.9 | IC50 | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
FUTIBATINIB
CHEMBL3701238
|
2022 |
|
|
INFIGRATINIB PHOSPHATE
CHEMBL1834657
|
2021 |
|
|
INFIGRATINIB
CHEMBL1852688
|
2021 |
|
|
PEMIGATINIB
CHEMBL4297522
|
2020 |
|
|
ERDAFITINIB
CHEMBL3545376
|
2019 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
PALBOCICLIB
CHEMBL189963
|
2015 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
TEMSIROLIMUS
CHEMBL1201182
|
2007 |
|
|
GEMCITABINE
CHEMBL888
|
1996 |
|
|
DOCETAXEL
CHEMBL3545252
|
1995 |
|
|
VINORELBINE
CHEMBL553025
|
1994 |
|
|
PACLITAXEL
CHEMBL428647
|
1992 |
|
|
ETOPOSIDE
CHEMBL44657
|
1983 |
|
|
MITOMYCIN
CHEMBL105
|
1981 |
|
|
DOXORUBICIN
CHEMBL53463
|
1974 |
|
|
CYTARABINE
CHEMBL803
|
1969 |
|
|
VINBLASTINE
CHEMBL159
|
1965 |
|
|
METHOTREXATE
CHEMBL34259
|
1953 |